JP2018145131A - 骨代謝改善用組成物及び骨代謝改善用食品 - Google Patents
骨代謝改善用組成物及び骨代謝改善用食品 Download PDFInfo
- Publication number
- JP2018145131A JP2018145131A JP2017040722A JP2017040722A JP2018145131A JP 2018145131 A JP2018145131 A JP 2018145131A JP 2017040722 A JP2017040722 A JP 2017040722A JP 2017040722 A JP2017040722 A JP 2017040722A JP 2018145131 A JP2018145131 A JP 2018145131A
- Authority
- JP
- Japan
- Prior art keywords
- bone metabolism
- bone
- formula
- composition
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004097 bone metabolism Effects 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 235000013305 food Nutrition 0.000 title claims abstract description 13
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 229930182470 glycoside Natural products 0.000 claims abstract description 17
- 150000002338 glycosides Chemical class 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 150000002148 esters Chemical class 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 26
- 230000006872 improvement Effects 0.000 claims description 11
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 239000002699 waste material Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 4
- 208000029725 Metabolic bone disease Diseases 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 abstract 1
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 87
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 210000000988 bone and bone Anatomy 0.000 description 15
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 14
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 14
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- -1 geranyl compound Chemical class 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 208000030159 metabolic disease Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000037182 bone density Effects 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229940122361 Bisphosphonate Drugs 0.000 description 3
- 244000207620 Euterpe oleracea Species 0.000 description 3
- 235000012601 Euterpe oleracea Nutrition 0.000 description 3
- 240000000599 Lentinula edodes Species 0.000 description 3
- 235000001715 Lentinula edodes Nutrition 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- 230000037118 bone strength Effects 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 0 COc1cc(C(O)=O)cc(*)c1O Chemical compound COc1cc(C(O)=O)cc(*)c1O 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 235000003650 acai Nutrition 0.000 description 2
- 239000010472 acai oil Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 125000005640 glucopyranosyl group Chemical group 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000544270 Angelica acutiloba Species 0.000 description 1
- 241000252073 Anguilliformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940037448 calcitonin preparations Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000003071 maltose group Chemical group 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229950006156 teprenone Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
で示される化合物、その塩もしくはエステル、又はそれらの配糖体を有効成分として含む骨代謝改善用組成物。
(2)式(I)で示される化合物、その塩もしくはエステル、又はそれらの配糖体を、組成物全量を100質量部として、0.1〜20質量部含む、上記(1)に記載の骨代謝改善用組成物。
(3)キノコ廃培地の抽出物又はその処理物である、上記(1)又は(2)に記載の骨代謝改善用組成物。
(4)骨代謝改善が、骨粗鬆症の予防又は治療である、上記(1)〜(3)のいずれか1つに記載の骨代謝改善用組成物。
(5)式(I)
で示される化合物、その塩もしくはエステル、又はそれらの配糖体を含む骨代謝改善用食品。
(6)骨代謝改善が、骨粗鬆症の予防又は治療である、上記(5)に記載の骨代謝改善用食品。
本実施形態に係る組成物は、式(I)
(1)薬剤
シリンガ酸(>97%純度)は、東京化成工業(株)から購入した。また、試験において使用する他の薬剤は全て高純度のものを用いた。
雌性ddYマウスは、日本エスエルシー(株)から購入した。各マウスは、個別のケージで、20±2℃、12時間/12時間の明暗サイクルの条件で飼育した。試験期間中、体重及び食物摂取量を週に一回測定した。11週齢の雌性ddYマウスに卵巣摘出手術(OVX)を実施し、骨粗鬆症モデルマウスを作製した群、並びに偽手術(sham)を実施した群を、それぞれ1週間の予備飼育後、一般状態に異常がみられなかったマウスを選択し、OVX及びshamのそれぞれをシリンガ酸(SA)摂取群及び非摂取群の2群に分け、計4群に分けた。
普通飼料は表1に示した組成で調製し、シリンガ酸含飼料は表1で示した飼料に100mg/kg体重/日(5.0gの飼料中、3mgシリンガ酸/30gマウス/日に相当)の用量となるように飼料に混ぜて調製した。飼料又は水は各々自由摂取させた。
以下の工程に従ってシリンガ酸及びバニリン酸の抽出を行った。
(1)50ml容ネジ口試験官に入れた試料をオートクレーブ処理(121℃、20分間)した。これにメタノール(40〜50ml)及び飽和炭酸水素ナトリウム水溶液(1ml)をこの順で加え、時々撹拌及び超音波処理を行いながら50℃で一晩(又は2時間)抽出し、得られた抽出液を濾過し、濾液をエバポレーターにて濃縮した。
(2)得られた残渣に、酢酸エチル(5ml)、飽和炭酸水素ナトリウム水溶液3ml及び蒸留水2mlを加えてボルテックスミキサーを用いて撹拌し、酢酸エチルと水とで二層分配した。
(3)得られた水層(下層)に、酢酸エチル(5ml)を加え、ボルテックスミキサーを用いて撹拌し、酢酸エチルと水とで二層分配した。
(4)得られた水層(下層)に濃塩酸(1ml)を加えてpH3以下とし、これに酢酸エチル(5ml)を加えて、ボルテックスミキサーを用いて撹拌し、酢酸エチルと水とで二層分配した。
(5)得られた酢酸エチル層(上層)をエバポレーターで濃縮させて残渣として抽出物を得た。
カラム:COSMOSIL 5C18AR−II(ナカライテスク社)
流速:0.5ml/分
移動相:
0〜45分 :10%メタノール/水から50%メタノール/水への直線勾配
45〜50分:50%メタノール/水から80%メタノールへの直線勾配
50〜80分:80%メタノール/水。
Claims (6)
- 式(I)で示される化合物、その塩もしくはエステル、又はそれらの配糖体を、組成物全量を100質量部として、0.1〜20質量部含む、請求項1に記載の骨代謝改善用組成物。
- キノコ廃培地の抽出物又はその処理物である、請求項1又は2に記載の骨代謝改善用組成物。
- 骨代謝改善が、骨粗鬆症の予防又は治療である、請求項1〜3のいずれか1項に記載の骨代謝改善用組成物。
- 骨代謝改善が、骨粗鬆症の予防又は治療である、請求項5に記載の骨代謝改善用食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017040722A JP7048025B2 (ja) | 2017-03-03 | 2017-03-03 | 骨代謝改善用組成物及び骨代謝改善用食品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017040722A JP7048025B2 (ja) | 2017-03-03 | 2017-03-03 | 骨代謝改善用組成物及び骨代謝改善用食品 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018145131A true JP2018145131A (ja) | 2018-09-20 |
JP7048025B2 JP7048025B2 (ja) | 2022-04-05 |
Family
ID=63590624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017040722A Active JP7048025B2 (ja) | 2017-03-03 | 2017-03-03 | 骨代謝改善用組成物及び骨代謝改善用食品 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7048025B2 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004521883A (ja) * | 2000-12-29 | 2004-07-22 | キフアン ヤオヨケジ トウジ ヨウザイアン ゼレン ゴングシ | 骨粗鬆症治療用RhizomaDrynariaeエキス及びその抽出法 |
JP2005132812A (ja) * | 2003-10-08 | 2005-05-26 | Kobayashi Pharmaceut Co Ltd | シイタケ菌糸体抽出物の分画物およびその用途 |
-
2017
- 2017-03-03 JP JP2017040722A patent/JP7048025B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004521883A (ja) * | 2000-12-29 | 2004-07-22 | キフアン ヤオヨケジ トウジ ヨウザイアン ゼレン ゴングシ | 骨粗鬆症治療用RhizomaDrynariaeエキス及びその抽出法 |
JP2005132812A (ja) * | 2003-10-08 | 2005-05-26 | Kobayashi Pharmaceut Co Ltd | シイタケ菌糸体抽出物の分画物およびその用途 |
Non-Patent Citations (1)
Title |
---|
NUTRIENTS, vol. 6, JPN6020050771, 2014, pages 1737 - 1751, ISSN: 0004593798 * |
Also Published As
Publication number | Publication date |
---|---|
JP7048025B2 (ja) | 2022-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6140365A (en) | Preparation of microorganisms comprising omega-3-fatty acid for use as a prophylactic or therapeutic agent against parasitic diseases of animals | |
JP6081024B2 (ja) | モノアセチルジアシルグリセロール化合物を有効成分として含有する関節リウマチの予防または治療用組成物 | |
JP5080284B2 (ja) | 骨疾患の予防及び/又は治療用医薬組成物、その組成物を含有する機能性食品、健康食品及び医薬製剤、並びに歯根−歯周組織形成促進剤 | |
EP3064209B1 (en) | Composition comprising ginsenoside f2 for preventing or treating insulin resistance | |
WO2013074273A1 (en) | Bidens pilosa and polyacetylenic compounds for prevention and treatment of coccidiosis | |
Senanayake et al. | The effects of bitter melon (Momordica charantia) extracts on serum and liver lipid parameters in hamsters fed cholesterol-free and cholesterol-enriched diets | |
JP6272646B2 (ja) | axial−equatorial aryl配向のfurofuran型リグナンを含有する骨形成促進用医薬組成物、その組成物を含有する医薬製剤、その組成物を含む機能性食品及び健康食品 | |
EP2992933A1 (en) | Ginsenoside f2 for prophylaxis and treatment of liver disease | |
JP6735224B2 (ja) | アストロサイトのグルコース代謝活性化剤 | |
WO2014030763A1 (ja) | 抗腫瘍剤 | |
Adane et al. | The developmental toxicity of Thymus schimperi essential oil in rat embryos and fetuses | |
JP2009114101A (ja) | 歯周病の予防又は治療用の医薬組成物、口腔衛生剤、並びに食品組成物 | |
JPWO2006120974A1 (ja) | 軟骨代謝異常疾患改善用健康食品及び医薬品組成物 | |
JP7048025B2 (ja) | 骨代謝改善用組成物及び骨代謝改善用食品 | |
JP5903280B2 (ja) | 整腸剤、便通改善剤、及び便秘改善剤 | |
JP5771412B2 (ja) | 持久力向上剤 | |
WO2020218148A1 (ja) | 過酸化脂質生成抑制剤 | |
JP2018145129A (ja) | 脂質代謝改善用組成物及び脂質代謝改善用食品 | |
JP5605023B2 (ja) | 4−ビニルフェノール系化合物 | |
JP5917499B2 (ja) | パナキサジオール含有組成物 | |
JP6107182B2 (ja) | 循環器系疾患の予防・治療効果を有するヒドロキシスチルベン類・フェルラ酸反応生成物 | |
JP2023146384A (ja) | レスベラトロール誘導体の新規製造法及び新規用途 | |
CN117695296A (zh) | 一种有机硒化合物在预防或治疗代谢性疾病中的应用 | |
JP2024051747A (ja) | 炎症性腸疾患改善剤、炎症性腸疾患改善用食品添加剤、炎症性腸疾患改善用飲食品、炎症性腸疾患改善用製剤 | |
JP5841168B2 (ja) | 抗腫瘍剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210430 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211025 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220301 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220314 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7048025 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |